The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion

[1]  K. Danø,et al.  Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. , 2005, European journal of biochemistry.

[2]  H. Johnsen,et al.  Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. , 1994, American journal of clinical pathology.

[3]  K. Danø,et al.  The murine urokinase-type plasminogen activator receptor gene. , 1994, The Journal of biological chemistry.

[4]  N. Brünner,et al.  A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumors , 1994, International journal of cancer.

[5]  N. Brünner,et al.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.

[6]  M. Ploug,et al.  Ligand Interaction between Urokinase-Type Plasminogen Activator and Its Receptor Probed with 8-Anilino-1-naphthalenesulfonate. Evidence for a Hydrophobic Binding Site Exposed Only on the Intact Receptor , 1994 .

[7]  M. Ploug,et al.  Structure—function relationships in the receptor for urokinase‐type plasminogen activator Comparison to other members of the Ly‐6 family and snake venom α‐neurotoxins , 1994 .

[8]  N. Brünner,et al.  Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion , 1994, International journal of cancer.

[9]  I. Campbell,et al.  Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein domain related to snake venom neurotoxins. , 1994, Biochemistry.

[10]  L. Lund,et al.  The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. , 1994, The Journal of investigative dermatology.

[11]  M. Gyetko,et al.  The urokinase receptor is required for human monocyte chemotaxis in vitro. , 1994, The Journal of clinical investigation.

[12]  P. Carmeliet,et al.  Physiological consequences of loss of plasminogen activator gene function in mice , 1994, Nature.

[13]  C. M. Fletcher,et al.  Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. , 1994, Structure.

[14]  B. Ljung,et al.  The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. , 1994, Cancer research.

[15]  N. E. Hansen,et al.  The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. , 1994, Blood.

[16]  L. Kirkeby,et al.  Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer , 1994, Histopathology.

[17]  D. Dichek,et al.  Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase. , 1994, The Journal of biological chemistry.

[18]  S. Rabbani,et al.  Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts , 1994, FEBS letters.

[19]  H. Nielsen,et al.  Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. , 1994, Journal of immunological methods.

[20]  K. Danø,et al.  A novel, specific pro‐urokinase complex on monocyte‐like cells, detected by transglutaminase‐catalyzed cross‐linking , 1993, FEBS letters.

[21]  K. Danø,et al.  Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. , 1993, The Biochemical journal.

[22]  F. Jänicke,et al.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. , 1993, The Journal of clinical investigation.

[23]  C. Clavel,et al.  Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. , 1993, Pathology, research and practice.

[24]  Y. Sugita,et al.  Determination of carboxyl-terminal residue and disulfide bonds of MACIF (CD59), a glycosyl-phosphatidylinositol-anchored membrane protein. , 1993, Journal of biochemistry.

[25]  A. Vaheri,et al.  Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[26]  U. Weidle,et al.  Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. , 1993, The Journal of biological chemistry.

[27]  M. Lisanti,et al.  Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells , 1993, The Journal of cell biology.

[28]  B. Nielsen,et al.  An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator , 1993, FEBS letters.

[29]  A. Levinson,et al.  Prevention of metastasis by inhibition of the urokinase receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[31]  F. Blasi,et al.  N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand. , 1993, The Journal of biological chemistry.

[32]  W. Schleuning,et al.  Interaction of urokinase‐type plasminogenactivator (u‐PA) with its cellular receptor (u‐PAR) induces phosphorylation on tyrosine of a 38 kDa protein , 1993, FEBS letters.

[33]  D. Miles,et al.  Activity of type IV collagenases in benign and malignant breast disease. , 1993, British Journal of Cancer.

[34]  G. Stamp,et al.  Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. , 1993, Journal of clinical pathology.

[35]  N. Brünner,et al.  Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. , 1993, Cancer research.

[36]  D. Rifkin,et al.  Bovine urokinase-type plasminogen activator and its receptor: cloning and induction by retinoic acid. , 1993, Gene.

[37]  K. Danø,et al.  Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. , 1993, The Journal of biological chemistry.

[38]  K. Danø,et al.  Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. , 1993, The Journal of biological chemistry.

[39]  M. Loriot,et al.  Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  K. Tryggvason,et al.  Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. , 1993, The American journal of pathology.

[41]  M. Ruggiero,et al.  Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. , 1993, Biochemical and biophysical research communications.

[42]  A. Aasen,et al.  Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas , 1993, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[43]  W. Birchmeier,et al.  Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. , 1992, The EMBO journal.

[44]  V. Ellis,et al.  The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer Invasion , 1992, Annals of the New York Academy of Sciences.

[45]  P. Chambon,et al.  Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. , 1992, The Journal of investigative dermatology.

[46]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[47]  D. Rifkin,et al.  The extracellular regulation of growth factor action. , 1992, Molecular biology of the cell.

[48]  L. Lund,et al.  Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. , 1992, The Journal of biological chemistry.

[49]  F. Blasi,et al.  Structural requirements for glycosyl-phosphatidylinositol-anchor attachment in the cellular receptor for urokinase plasminogen activator. , 1992, European journal of biochemistry.

[50]  B. Fleckenstein,et al.  Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. , 1992, Virology.

[51]  M. Llinás,et al.  Heparin binding to the urokinase kringle domain. , 1992, Biochemistry.

[52]  R Poulsom,et al.  Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. , 1992, The American journal of pathology.

[53]  S. Moestrup,et al.  Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. , 1992, The Journal of biological chemistry.

[54]  A. Mazar,et al.  Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. , 1992, The Journal of biological chemistry.

[55]  J. M. Ryan,et al.  The matrix metalloproteinase pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells. , 1992, The Journal of biological chemistry.

[56]  D. Dichek,et al.  Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation. , 1992, The Journal of biological chemistry.

[57]  M. Ploug,et al.  Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. , 1992, European journal of biochemistry.

[58]  N. E. Hansen,et al.  The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. , 1992, Blood.

[59]  T. Hurskainen,et al.  Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. , 1992, Cancer research.

[60]  L. Bolund,et al.  Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. , 1992, American journal of human genetics.

[61]  M. Duffy,et al.  Type‐1 plasminogen activator inhibitor in human breast carcinomas , 1992, International journal of cancer.

[62]  F. Blasi,et al.  Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract , 1991, The Journal of cell biology.

[63]  D. Powe,et al.  Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours , 1991, International journal of cancer.

[64]  F. Blasi,et al.  In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion , 1991, The Journal of cell biology.

[65]  L. Lund,et al.  Urokinase‐receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. , 1991, The EMBO journal.

[66]  L. Lund,et al.  Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. , 1991, The Journal of investigative dermatology.

[67]  D. Belin,et al.  The plasminogen activator/plasmin system. , 1991, The Journal of clinical investigation.

[68]  J. Saurat,et al.  Differential protease expression by cutaneous squamous and basal cell carcinomas. , 1991, The Journal of clinical investigation.

[69]  M. Ploug,et al.  Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor , 1991, FEBS letters.

[70]  S W Hall,et al.  Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. , 1991, The Journal of biological chemistry.

[71]  K. Danø,et al.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.

[72]  F. Jänicke,et al.  Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.

[73]  K. Danø,et al.  Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.

[74]  F. Blasi,et al.  A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. , 1991, The Journal of biological chemistry.

[75]  E. Rondeau,et al.  Growth factor-like effect of urokinase type plasminogen activator in human renal cells. , 1991, Biochemical and biophysical research communications.

[76]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[77]  F. Blasi,et al.  The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. , 1991, The Journal of biological chemistry.

[78]  L. Lund,et al.  Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. , 1991, The Journal of biological chemistry.

[79]  K. Danø,et al.  Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[80]  Jordi Félez,et al.  Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. , 1991, Biochemistry.

[81]  F. Blasi,et al.  Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. , 1991, The Journal of biological chemistry.

[82]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[83]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[84]  D. Weiner,et al.  Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. , 1990, Blood.

[85]  T. Tsuchiya,et al.  Structure of the snake short-chain neurotoxin, erabutoxin c, precursor gene. , 1990, European journal of biochemistry.

[86]  L. Orci,et al.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.

[87]  K. Danø,et al.  Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. , 1990, The Journal of biological chemistry.

[88]  J. Gliemann,et al.  Urokinase receptors in human monocytes. , 1990, Biochimica et biophysica acta.

[89]  E. Appella,et al.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. , 1990, The Journal of biological chemistry.

[90]  M. Cubellis,et al.  Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1. , 1990, The EMBO journal.

[91]  E. Appella,et al.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.

[92]  S. Stacey,et al.  Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.

[93]  E. Plow,et al.  Gangliosides interact directly with plasminogen and urokinase and may mediate binding of these fibrinolytic components to cells. , 1989, Biochemistry.

[94]  M. Cubellis,et al.  Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[95]  A. Vaheri,et al.  Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants , 1989, The Journal of cell biology.

[96]  M. Scully,et al.  Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. , 1989, The Journal of biological chemistry.

[97]  M. Cubellis,et al.  Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate , 1989, The Journal of cell biology.

[98]  D. Belin,et al.  Characterization of the cellular binding site for the urokinase-type plasminogen activator. , 1989, The Journal of biological chemistry.

[99]  L. Ossowski,et al.  In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase , 1988, The Journal of cell biology.

[100]  V Ottevanger,et al.  Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. , 1988, The Journal of investigative dermatology.

[101]  J. Baker,et al.  Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin , 1988, The Journal of cell biology.

[102]  F. Blasi,et al.  A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. , 1988, The Journal of biological chemistry.

[103]  L. Ossowski.  Plasminogen activator dependent pathways inthe dissemination of human tumor cells in the chick embryo , 1988, Cell.

[104]  A. Vaheri,et al.  Ultrastructural localization of plasma membrane-associated urokinase- type plasminogen activator at focal contacts , 1988, The Journal of cell biology.

[105]  M. Scully,et al.  Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study. , 1987, The Journal of biological chemistry.

[106]  B. Binder,et al.  Proliferation of a human epidermal tumor cell line stimulated by urokinase , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[107]  F. Blasi,et al.  Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors , 1987, The Journal of cell biology.

[108]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[109]  J. Plescia,et al.  The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type , 1986, The Journal of cell biology.

[110]  L. Ossowski,et al.  Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis , 1986, The Journal of experimental medicine.

[111]  K. Danø,et al.  Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. , 1986, The Journal of biological chemistry.

[112]  A. Corti,et al.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[113]  D. Belin,et al.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.

[114]  P. Verde,et al.  Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[115]  K. Danø,et al.  Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse , 1984, The Journal of cell biology.

[116]  L. Ossowski,et al.  Antibodies to plasminogen activator inhibit human tumor metastasis , 1983, Cell.

[117]  H. Jörnvall,et al.  Purification and characterization of a melanoma cell plasminogen activator. , 1983, European journal of biochemistry.

[118]  P. Seeburg,et al.  Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli , 1983, Nature.

[119]  J. Zeuthen,et al.  Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. , 1982, Biochemistry.

[120]  L. Flohé,et al.  The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. , 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[121]  K. Danø,et al.  Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of the cell factor, a plasminogen activator. , 1974, The Journal of biological chemistry.

[122]  D. Rifkin,et al.  AN ENZYMATIC FUNCTION ASSOCIATED WITH TRANSFORMATION OF FIBROBLASTS BY ONCOGENIC VIRUSES , 1973, The Journal of experimental medicine.

[123]  D. Rifkin,et al.  AN ENZYMATIC FUNCTION ASSOCIATED WITH TRANSFORMATION OF FIBROBLASTS BY ONCOGENIC VIRUSES , 1973, The Journal of experimental medicine.

[124]  R. Ormsbee,et al.  Experimental Alteration of the Ability of Tumor Cells to Lyse Plasma Clots in vitro ∗ , 1947, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[125]  A. Fischer.  Mechanism of the Proteolytic Activity of Malignant Tissue Cells , 1946, Nature.

[126]  R. A. Lambert,et al.  CHARACTERISTICS OF GROWTH OF SARCOMA AND CARCINOMA CULTIVATED IN VITRO , 1911, The Journal of experimental medicine.

[127]  A. Carrel,et al.  CULTIVATION IN VITRO OF MALIGNANT TUMORS , 1911, The Journal of experimental medicine.

[128]  P. Kristensen,et al.  The Plasminogen Activation System in Human Colon Cancer : Messenger RNA for the Inhibitor PAI-1 Is Located in Endothelial Cells in the Tumor , 2006 .

[129]  N. Brünner,et al.  Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. , 1994, Cancer research.

[130]  P. Quax,et al.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. , 1994, The American journal of pathology.

[131]  U. Cavallaro,et al.  The urokinase receptor: Structure, regulation and inhibitor-mediated internalization , 1994 .

[132]  K. Koretz,et al.  Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. , 1993, European journal of cancer.

[133]  K. Danø,et al.  Cellular receptor for urokinase-type plasminogen activator: function in cell-surface proteolysis. , 1993, Methods in enzymology.

[134]  M. Ploug,et al.  Cellular receptor for urokinase-type plasminogen activator: protein structure. , 1993, Methods in enzymology.

[135]  Catherine,et al.  Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. , 1993, Cancer research.

[136]  C. Clavel,et al.  Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. , 1993, Invasion & metastasis.

[137]  N. Brünner,et al.  lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. , 1992, European journal of cancer.

[138]  L. Matrisian,et al.  Expression and localization of the matrix metalloproteinase pump‐1 (MMP‐7) in human gastric and colon carcinomas , 1991, Molecular carcinogenesis.

[139]  L. Ossowski,et al.  Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. , 1991, Cancer research.

[140]  L. Kirkeby,et al.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. , 1991, The American journal of pathology.

[141]  A. Vaheri,et al.  Directed plasminogen activation at the surface of normal and malignant cells. , 1991, Advances in cancer research.

[142]  R. Palfree.  The urokinase-type plasminogen activator receptor is a member of the Ly-6 superfamily. , 1991, Immunology today.

[143]  D. Rifkin,et al.  Cell-associated plasminogen activation: regulation and physiological functions. , 1988, Annual review of cell biology.

[144]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[145]  E. Holmgren,et al.  Isolation of cDNA sequences coding for a part of human tissue plasminogen activator. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[146]  R. Hider,et al.  Conformational properties of the neurotoxins and cytotoxins isolated from Elapid snake venoms. , 1983, CRC critical reviews in biochemistry.

[147]  W. Gunzler.  The primary structure of high molecular mass urokinase from human urine , 1982 .

[148]  E. Reich.  ACTIVATION OF PLASMINOGEN: A GENERAL MECHANISM FOR PRODUCING LOCALIZED EXTRACELLULAR PROTEOLYSIS , 1978 .

[149]  Dacie Jv,et al.  Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease. , 1972, Series haematologica.